• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 POS filed by Intricon Corporation

    5/24/22 5:07:14 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care
    Get the next $IIN alert in real time by email
    S-8 POS 1 ny20003464x5-x16_s8pos.htm S-8 POS
    As filed with the Securities and Exchange Commission on May 24, 2022
     
    Registration No.  333-263900
    Registration No.  333-211326
    Registration No.  333-204123
    Registration No.  333-181160
    Registration No.  333-173837
    Registration No.  333-168586
    Registration No.  333-145577
    Registration No.  333-134256
    Registration No.  333-129104
    Registration No.  333-66433
    Registration No.  333-59694
    Registration No.  333-16377


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549
              



    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-263900
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-211326
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-204123
    Post-Effective Amendment No. 2 to Form S-8 Registration No. 333-181160
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-173837
    Post-Effective Amendment No. 2 to Form S-8 Registration No. 333-168586
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-145577
    Post-Effective Amendment No. 2 to Form S-8 Registration No. 333-134256
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-129104
    Post-Effective Amendment No. 1 to Form S-8 Registration No 333-66433
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-59694
    Post-Effective Amendment No. 1 to Form S-8 Registration No. 333-16377

    under
    The Securities Act of 1933
              



    INTRICON CORPORATION
    (Exact name of registrant as specified in its charter)

    Pennsylvania
    (State or other jurisdiction of
    incorporation or organization)
    23-1069060
    (I.R.S. employer
    identification no.)

    1260 Red Fox Road, Arden Hills, MN 55112
     (Address of principal executive offices, including zip code)

    Amended and Restated 2015 Equity Incentive Plan, as amended
    2007 Employee Stock Purchase Plan, as amended
    2006 Equity Incentive Plan, as amended
    Amended and Restated Non-Employee Directors’ Stock Option Plan
    2001 Stock Option Plan
    1994 Stock Option Plan
    (Full title of the plan)

    Scott Longval, President and Chief Executive Officer
    Intricon Corporation
    1260 Red Fox Road, Arden Hills, MN 55112
    (Name and address of agent for service)

    (651) 636-9770
    (Telephone number, including area code, of agent for service)

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer ☐
     
    Accelerated filer ☒
    Non-accelerated filer ☐
     
    Smaller reporting company ☒
    Emerging growth company ☐
       

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐


    DEREGISTRATION OF SECURITIES

    These Post-Effective Amendments relate to the following Registration Statements on Form S-8 (the “Registration Statements”) filed by Intricon Corporation (the “Company”) with the U.S. Securities and Exchange Commission (the “SEC”):

    •
    Registration No. 333-263900, filed with the SEC on March 28, 2022, pertaining to the registration of 500,000 shares of the Company’s common stock, par value $1.00 per share (the “Common Stock”), issuable pursuant to the Company’s Amended and Restated 2015 Equity Incentive Plan, as amended.

    •
    Registration No. 333-211326, filed with the SEC on May 12, 2016, pertaining to the registration of 100,000 shares of Common Stock issuable pursuant to the Company’s 2007 Employee Stock Purchase Plan, as amended.

    •
    Registration No. 333-204123, filed with the SEC on May 13, 2015 pertaining to the registration of 500,214 shares of Common Stock issuable pursuant to the Company’s 2015 Equity Incentive Plan.

    •
    Registration No. 333-181160, filed with the SEC on May 4, 2012 pertaining to the registration of 300,000 shares of Common Stock issuable pursuant to the Company’s 2006 Equity Incentive Plan, as amended.

    •
    Registration No. 333-173837, filed with the SEC on May 2, 2011 pertaining to the registration of 100,000 shares of Common Stock issuable pursuant to the Company’s 2007 Employee Stock Purchase Plan, as amended.

    •
    Registration No. 333-168586, filed with the SEC on August 6, 2010 pertaining to the registration of 250,000 shares of Common Stock issuable pursuant to the Company’s 2006 Equity Incentive Plan, as amended.

    •
    Registration No. 333-145577, filed with the SEC on August 20, 2007 pertaining to the registration of 100,000 shares of Common Stock issuable pursuant to the Company’s 2007 Employee Stock Purchase Plan.

    •
    Registration No. 333-134256, filed with the SEC on May 18, 2006 pertaining to the registration of 1,217,500 shares of Common Stock issuable pursuant to the Company’s 2006 Equity Incentive Plan.

    •
    Registration No. 333-129104, filed with the SEC on October 18, 2005 pertaining to the registration of 175,000 shares of Common Stock issuable pursuant to the Company’s Amended and Restated Non-Employee Directors’ Stock Option Plan.

    •
    Registration No 333-66433, filed with the SEC on October 30, 1998 pertaining to the registration of 75,000 shares of Common Stock issuable pursuant to the Company’s Non-Employee Directors’ Stock Option Plan.

    •
    Registration No. 333-59694, filed with the SEC on April 27, 2001 pertaining to the registration of 1,000,000 shares of Common Stock issuable pursuant to the Company’s 2001 Stock Option Plan.

    •
    Registration No. 333-16377, filed with the SEC on November 19, 1996 pertaining to the registration of 300,000 shares of Common Stock issuable pursuant to the Company’s 1994 Stock Option Plan.
    2

    The Company is filing these Post-Effective Amendments to the Registration Statements to withdraw and remove from registration any and all unissued securities issuable by the Company pursuant to the above referenced Registration Statements.

    On May 24, 2022, pursuant to the terms of an Agreement and Plan of Merger, dated as of February 27, 2022 (the “Merger Agreement”), by and among the Company, IIN Holding Company LLC, a Delaware limited liability company (“Parent”), and IC Merger Sub Inc., a Pennsylvania corporation and a wholly owned subsidiary of Parent (“Merger Sub”), Merger Sub merged with and into the Company, with the Company surviving the merger as a wholly-owned subsidiary of Parent (the “Merger”), at which time the Company’s equity securities ceased to be publicly traded.

    As a result of the Merger, the Company has terminated all offerings of its securities pursuant to the Registration Statements.  In accordance with an undertaking made by the Company in each of the Registration Statements to remove from registration, by means of a post-effective amendment, any securities which remain unsold at the termination of the offering, the Company hereby removes from registration any and all securities registered under the Registration Statements, which remain unsold as of the date hereof, and terminates the effectiveness of the Registration Statements.
    3

    SIGNATURES

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all the requirements for filing on Form S-8 and has duly caused these Post-Effective Amendments to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Minneapolis, State of Minnesota, on the 24th day of May, 2022.

     
    INTRICON CORPORATION
     
    By:
    /s/ Scott Longval
     
    Scott Longval
    President and Chief Executive Officer

    No other person is required to sign these Post-Effective Amendments to the Registration Statements in reliance on Rule 478 under the Securities Act of 1933, as amended.


    Get the next $IIN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $IIN

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IIN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Giordano Nicholas A gifted 4,000 shares and returned 110,925 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:49:14 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Smith Philip Irving returned 16,327 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:43:53 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Gorder Mark Stephen returned 373,709 shares to the company, closing all direct ownership in the company

    4 - INTRICON CORP (0000088790) (Issuer)

    5/25/22 2:46:42 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Intricon Announces Completion of Acquisition by an Affiliate of Altaris Capital Partners

    ARDEN HILLS, Minn., May 24, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced the completion of its acquisition by funds affiliated with Altaris Capital Partners, LLC (together with certain affiliated entities, "Altaris") for $24.25 per share in cash, or approximately $241 million on a fully diluted basis. The transaction was announced on February 28, 2022, and received approval from stockholders on May 24, 2022. As a result of the transaction, Intricon is now a privately he

    5/24/22 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Enters into Agreement to be Acquired by an Affiliate of Altaris Capital Partners for $241 Million

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced that it has entered into a definitive agreement whereby an affiliate of Altaris Capital Partners, LLC (collectively with its affiliates, "Altaris"), an investment firm focused exclusively on the healthcare industry, will acquire the company. Under the terms of the agreement, Altaris will acquire all outstanding shares of Intricon for $24.25 per share in a transaction that values Intricon at an equ

    2/28/22 8:35:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley resumed coverage on IntriCon with a new price target

    B. Riley resumed coverage of IntriCon with a rating of Buy and set a new price target of $32.00 from $28.00 previously

    2/26/21 9:37:25 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    SEC Filings

    View All

    SEC Form 15-12B filed by Intricon Corporation

    15-12B - INTRICON CORP (0000088790) (Filer)

    6/3/22 10:36:21 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - INTRICON CORP (0000088790) (Filer)

    5/25/22 3:55:57 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Intricon Corporation

    S-8 POS - INTRICON CORP (0000088790) (Filer)

    5/24/22 5:07:27 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Leadership Updates

    Live Leadership Updates

    View All

    Intricon Appoints Kathleen Pepski to its Board of Directors Intricon Corporation

    ARDEN HILLS, Minn., March 22, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced the appointment of Kathleen Pepski to the company’s Board of Directors, effective March 19, 2021. “We are delighted to welcome Kathleen to Intricon and our board of directors,” said Scott Longval, President and Chief Executive Officer of Intricon. “Kathleen is a well-respected business leader in Minneapolis whose background in manufacturing and distribution, as well as mergers and acquisitions, will be instrumental in our long

    3/22/21 8:00:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Corporation Announces Appointment of Chief Financial Officer

    ARDEN HILLS, Minn., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ: IIN), an international company engaged in designing, developing, engineering, and manufacturing miniature interventional, implantable and body-worn medical devices, today announced that Ellen Scipta has been appointed Chief Financial Officer (CFO), effective immediately. As a key member of Intricon's executive leadership team, Ms. Scipta will lead the company’s financial operations and aid the management team on growing Intricon. “We are extremely pleased to welcome a strong leader like Ellen to the Intricon team. Her unique skill set that blends engineering with extensive financial experience will be inva

    2/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Financials

    Live finance-specific insights

    View All

    Intricon Reports Fourth Quarter and Full Year 2021 Results

    ARDEN HILLS, Minn., Feb. 28, 2022 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its fourth quarter and year ended December 31, 2021. Fourth Quarter Highlights: Revenue of $32.2 million compared to $30.3 million in the prior year period Diabetes revenue increased 2% compared to the prior yearOther medical revenue increased 36.1% over the prior year period Gross profit margin of 25.2%, compared to 25.7% in the prior year periodNet income of $0.00 per di

    2/28/22 8:40:00 AM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Reports Third Quarter 2021 Results

    ARDEN HILLS, Minn., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, today announced financial results for its third quarter ended September 30, 2021. Third Quarter 2021 Highlights: Revenue of $31.1 million, a 13.5% increase compared to the prior year periodGross profit margin of 23.1%, compared to 26.3% in the prior year periodGAAP net income of $337,000 versus net income of $644,000 in the prior year periodNon-GAAP adjusted net income of $1.7 million versus $2.4 m

    11/8/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    Intricon Announces CFO Departure and Preliminary Third Quarter 2021 Revenue

    ARDEN HILLS, Minn., Oct. 29, 2021 (GLOBE NEWSWIRE) -- Intricon Corporation (NASDAQ:IIN), an international joint development manufacturer engaged in designing, developing, engineering, manufacturing, and packaging miniature interventional, implantable and body-worn medical devices, announced today that Ellen Scipta has stepped down from her position as Chief Financial Officer, effective October 29, 2021. Annalee Lutgen, current Treasurer and Director of Finance, will serve as interim Chief Financial Officer effective upon Ms. Scipta's resignation as the company conducts its search for a permanent replacement. "We appreciate the contributions Ellen has made to Intricon during her tenure h

    10/29/21 4:05:00 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    $IIN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/26/22 4:04:17 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/23/22 4:14:23 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Intricon Corporation (Amendment)

    SC 13D/A - INTRICON CORP (0000088790) (Subject)

    5/19/22 4:06:37 PM ET
    $IIN
    Medical/Dental Instruments
    Health Care